EPI-STORM: Cytokine Storm in Organ Donors
Launched by UNIVERSITÉ DE SHERBROOKE · Dec 19, 2018
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The EPI-STORM trial is studying how the immune system reacts in organ donors who have suffered brain death, particularly focusing on kidneys and livers. When someone experiences neurological death, their body can go into a state of inflammation that may affect the quality of the organs available for transplantation. This trial aims to understand these inflammatory processes better, which could lead to improved treatments for donors and ultimately enhance the success of organ transplants for patients in need.
To participate in this study, donors must be adults aged 18 or older who have been declared brain dead and have consented to organ donation. The study will not include individuals with certain infections, cancers, or those who have been on immunosuppressive therapy for an extended period. Participants will be closely monitored in the intensive care unit to gather important information about their health and the condition of the organs for transplantation. This research is crucial because it aims to increase the number of viable organs available and improve the survival rates of patients receiving these transplants.
Gender
ALL
Eligibility criteria
- Phase 1 of the study:
- Inclusion Criteria:
- • Patient admitted to the intensive care unit with a serious neurologic lesion
- • Glasgow Coma Scale score ≤ 4
- • Absence of sedation for the last 6 hours
- • Age ≥ 18 years old
- Exclusion Criteria:
- • S. aureus bacteremia
- • Active neoplasia
- • Receiving immunosuppressive therapy (including steroids) for \> 3 months
- Specific to potential liver donors:
- • Hepatic insufficiency defined as i) INR \> 1.5, ii) hepatic encephalopathy, iii) AST, ALT \> 2 times normal value
- Specific to potential kidney donors:
- • Polycystic kidney disease
- • Chronic renal failure (i.e., eGFR \< 60 ml/min)
- Phase 2 of the study:
- Inclusion Criteria:
- • Organ donor after neurologic death (DND) declaration as determined by the attending physician
- • Consent to organ donation obtained
About Université De Sherbrooke
The Université de Sherbrooke is a leading research institution in Canada, renowned for its commitment to advancing knowledge and innovation in various fields, including health sciences. With a focus on interdisciplinary collaboration, the university actively engages in clinical trials to explore new therapeutic interventions and improve patient care. Its research team comprises experienced professionals dedicated to ensuring the highest ethical standards and scientific rigor in clinical research. The Université de Sherbrooke strives to translate research findings into practical solutions that enhance health outcomes and contribute to the advancement of medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Montréal, Quebec, Canada
Sherbrooke, Quebec, Canada
Montréal, Quebec, Canada
Quebec City, Quebec, Canada
Patients applied
Trial Officials
Dr Frédérick D'Aragon, MD FRCPC MSc
Principal Investigator
Université de Sherbrooke
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials